公开(公告)号：US20170348329A1

公开(公告)日：2017-12-07

申请号：US15684240

申请日：2017-08-23

申请人： GLAXOSMITHKLINE LLC

发明人： Joel David GRESHOCK ,  Kurtis Earl BACHMAN ,  Samuel Charles BLACKMAN

IPC分类号： A61K31/58 ,  A61K9/20 ,  A61K31/5377 ,  A61K9/00 ,  A61K9/48 ,  A61K47/10

CPC分类号： A61K31/58 ,  A61K9/0019 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2059 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K31/5377 ,  A61K47/10 ,  A61K2300/00

摘要： A novel combination comprising the 17 α-hydroxylase/C17,20 lyase inhibitor, (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or solvate thereof, with a PI3Kβ inhibitor, 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 α-hydroxylase/C17,20 lyase and/or PI3Kβ is beneficial, e.g., cancer.

公开(公告)号：US20150352121A1

公开(公告)日：2015-12-10

申请号：US14759742

申请日：2014-02-19

申请人： GLAXOSMITHKLINE LLC

发明人： Kurtis Earl BACHMAN ,  Joel David GRESHOCK ,  Mary Ann HARDWICKE

IPC分类号： A61K31/5377 ,  A61K31/047 ,  A61K31/185 ,  A61K31/506

CPC分类号： A61K31/5377 ,  A61K31/047 ,  A61K31/185 ,  A61K31/506 ,  A61K2300/00

摘要： A novel combination comprising the PI3K-β inhibitor 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of PI3K-β and/or B-Raf is beneficial, eg. cancer.

摘要翻译： 包含PI3K-和bgr的新型组合; 抑制剂2-甲基-1 - {[2-甲基-3-（三氟甲基）苯基]甲基} -6-（4-吗啉基）-1H-苯并咪唑-4-羧酸或其药学上可接受的盐与B -Raf抑制剂，特别是N- {3- [5-（2-氨基-4-嘧啶基）-2-（1,1-二甲基乙基）-1,3-噻唑-4-基] -2-氟苯基} -2 ，6-二氟苯磺酰胺或其药学上可接受的盐，包含该组合物的药物组合物和使用这些组合和组合物在治疗PI3K-＆bgr; 和/或B-Raf是有益的，例如。 癌症。